Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foster versus Symbicort in severe to very severe COPD
NL-OMON38416Phase 3Active, not recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Sep 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of beclometasone dipropionate + formoterol and budesonide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Change from baseline to end of treatment in post-dose residual volume. Started Sep 2011; status: active, not recruiting.
02
Drugs
beclometasone dipropionate + formoterolbudesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON38416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38416.